We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biotech Company Develops from Laboratory and Clinical Studies

By LabMedica International staff writers
Posted on 04 Aug 2010
A new biotech company aims to improve the diagnosis of diabetes and cancer.

The startup company, which developed from diabetes and genomic research, will offer biomedical institutions and pharmaceutical industries, services and research reagents. More...


Providing a variety of high-throughput scientific services the new company, Jinfiniti Biosciences, LLC is housed in the Medical College of Georgia (MCG) Life Sciences Business Development Center (Augusta, GA, USA). It offers nucleic acid isolation, genomic analysis, antibody production, immunoassays, medicinal chemistry, toxicity evaluation for clinical laboratories, academic and pharmaceutic institutions, and forensics.

Biomarkers are also being developed that will enable the introduction of simple urine and/or blood tests for early disease detection, diagnosis, and monitoring of treatment outcomes. Additionally, the company is developing new drugs and companion biomarkers for personalized medicine.

Dr. Jin-Xiong She, director of the MCG Center for Biotechnology and Genomic Medicine and president and CEO of the new company, said, "There are many wonderful scientific discoveries but the vast majority never translates into medical practice." Dr. She wants to help scientists close that gap. "That is what startup companies are trying to do: take discoveries to the next step so that big companies become interested."

Jinfiniti Biosciences, LLC focuses on commercialization of technologies and discoveries developed by the company founder, Dr. Jin-Xiong She. He is an authority in the fields of high throughput technologies in genomics, proteomics, and biomarker and drug development.

Related Links:
Jinfiniti Biosciences, LLC
Medical College of Georgia Life Sciences Business Development Center



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.